Kudzu Treatment for Alcohol Abuse (KUDZU)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01596231|
Recruitment Status : Completed
First Posted : May 10, 2012
Results First Posted : October 21, 2014
Last Update Posted : October 21, 2014
|Condition or disease||Intervention/treatment||Phase|
|Alcohol Consumption||Dietary Supplement: Kudzu Dietary Supplement: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Isoflavone (Kudzu) Extract Effects on Alcohol Drinking: Single Dose Pretreatment Study|
|Study Start Date :||May 2010|
|Actual Primary Completion Date :||May 2013|
|Actual Study Completion Date :||July 2014|
Placebo Comparator: Placebo
This is a study designed to test whether a single administration of kudzu extract (2 mg) or placebo will significantly reduce the number of drinks consumed during a single 1 ½ hours drinking session when given as a pretreatment 2 ½ hours before the drinking session.
Dietary Supplement: Placebo
Placebo will be administered as a pretreatment 2 ½ hours before a drinking session
Active Comparator: Kudzu
Dietary Supplement: Kudzu
Kudzu (2 mg) will be administered as a pretreatment 2 ½ hours before a drinking session to see if it will significantly reduce the number of drinks consumed during a single 1 ½ hours drinking session.
- Drinking Behaviors [ Time Frame: Study end ]A variety of measures describing the drinking behavior will be analyzed with appropriate parametric tests (t-test, analysis of variance): number of beers consumed, weight and volume consumed, sip analysis (number, interlude), and latency (time to open first and subsequent drinks).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01596231
|United States, Massachusetts|
|Belmont, Massachusetts, United States, 02478|
|Principal Investigator:||Scott E. Lukas, Ph.D.||Mclean Hospital|